DK1113021T3 - Polyamid-oligonukleotid-derivater, deres fremstilling og anvendelse - Google Patents

Polyamid-oligonukleotid-derivater, deres fremstilling og anvendelse

Info

Publication number
DK1113021T3
DK1113021T3 DK01104012T DK01104012T DK1113021T3 DK 1113021 T3 DK1113021 T3 DK 1113021T3 DK 01104012 T DK01104012 T DK 01104012T DK 01104012 T DK01104012 T DK 01104012T DK 1113021 T3 DK1113021 T3 DK 1113021T3
Authority
DK
Denmark
Prior art keywords
dna
pna
polyamide
oligonucleotide derivatives
rna
Prior art date
Application number
DK01104012T
Other languages
English (en)
Inventor
Eugen Uhlmann
Gerhard Breipohl
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1113021T3 publication Critical patent/DK1113021T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01104012T 1994-03-14 1995-03-08 Polyamid-oligonukleotid-derivater, deres fremstilling og anvendelse DK1113021T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4408528A DE4408528A1 (de) 1994-03-14 1994-03-14 Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
EP95103332A EP0672677B1 (de) 1994-03-14 1995-03-08 Polyamid-Oligonucleotid-Derivate, deren Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
DK1113021T3 true DK1113021T3 (da) 2006-12-11

Family

ID=6512694

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95103332T DK0672677T3 (da) 1994-03-14 1995-03-08 Polyamid-oligonucleotid-derivater, deres fremstilling og anvendelse
DK01104012T DK1113021T3 (da) 1994-03-14 1995-03-08 Polyamid-oligonukleotid-derivater, deres fremstilling og anvendelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK95103332T DK0672677T3 (da) 1994-03-14 1995-03-08 Polyamid-oligonucleotid-derivater, deres fremstilling og anvendelse

Country Status (14)

Country Link
EP (2) EP1113021B1 (da)
JP (1) JP4620810B2 (da)
KR (1) KR100416864B1 (da)
CN (1) CN100379756C (da)
AT (2) ATE335760T1 (da)
AU (1) AU698210B2 (da)
CA (1) CA2144475C (da)
DE (3) DE4408528A1 (da)
DK (2) DK0672677T3 (da)
ES (2) ES2269239T3 (da)
FI (2) FI117135B (da)
HK (2) HK1038568A1 (da)
NO (1) NO314664B1 (da)
PT (2) PT672677E (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710164B1 (en) 1993-11-22 2004-03-23 Peter E. Nielsen Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
DE59607750D1 (de) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19532553A1 (de) * 1995-09-04 1997-03-06 Hoechst Ag Verfahren zur Herstellung substituierter N-Ethyl-Glycinderivate
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
ES2221942T3 (es) * 1996-05-24 2005-01-16 Aventis Pharma Deutschland Gmbh Reactivo y metodo para inhibir la expresion de n-ras.
WO1997045115A1 (en) * 1996-05-31 1997-12-04 Trophix Pharmaceuticals, Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
DE69734783T2 (de) * 1996-07-24 2006-08-17 Buchardt, Dorte Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
DE19637339A1 (de) * 1996-09-13 1998-03-19 Hoechst Ag Verfahren zur Amplifikation von Nukleinsäuren
EP2341058A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
WO1999034014A2 (en) * 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
US5952202A (en) * 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6316230B1 (en) 1999-08-13 2001-11-13 Applera Corporation Polymerase extension at 3′ terminus of PNA-DNA chimera
US7205105B2 (en) 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
DE10019135A1 (de) 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
US7348146B2 (en) 2003-10-02 2008-03-25 Epoch Biosciences, Inc. Single nucleotide polymorphism analysis of highly polymorphic target sequences
CA2542768A1 (en) 2003-10-28 2005-05-12 Epoch Biosciences, Inc. Fluorescent probes for dna detection by hybridization with improved sensitivity and low background
DE102006034319A1 (de) * 2006-07-21 2008-01-31 Ugichem Gmbh Chirale mit Phosponsäurester- oder Phosphonsäure- substituierte Verbindungen
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856406T2 (de) * 1987-10-28 2000-10-19 Florey Howard Inst Oligonucleotid-polyamid konjugate
WO1993024511A1 (en) * 1992-05-29 1993-12-09 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
IL104461A (en) * 1992-01-22 2001-05-20 Hoechst Ag Analogs of oligonucleotide, their preparation and pharmaceutical preparations containing them
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use

Also Published As

Publication number Publication date
FI117135B (fi) 2006-06-30
NO314664B1 (no) 2003-04-28
CN100379756C (zh) 2008-04-09
DE4408528A1 (de) 1995-09-28
FI951132A (fi) 1995-09-15
CN1112126A (zh) 1995-11-22
AU698210B2 (en) 1998-10-29
JPH07278179A (ja) 1995-10-24
EP1113021A2 (de) 2001-07-04
FI117939B (fi) 2007-04-30
PT672677E (pt) 2002-11-29
FI951132A0 (fi) 1995-03-10
EP1113021B1 (de) 2006-08-09
EP0672677A3 (de) 1996-01-17
ES2269239T3 (es) 2007-04-01
DE59510252D1 (de) 2002-08-08
JP4620810B2 (ja) 2011-01-26
KR950032265A (ko) 1995-12-20
NO950955L (no) 1995-09-15
FI20051072A (fi) 2005-10-24
AU1479895A (en) 1995-09-21
KR100416864B1 (ko) 2006-01-27
HK1038568A1 (en) 2002-03-22
CA2144475A1 (en) 1995-09-15
CA2144475C (en) 2010-06-08
PT1113021E (pt) 2006-12-29
EP0672677A2 (de) 1995-09-20
ES2179080T3 (es) 2003-01-16
EP0672677B1 (de) 2002-07-03
DK0672677T3 (da) 2002-10-28
ATE335760T1 (de) 2006-09-15
HK1012003A1 (en) 1999-07-23
EP1113021A3 (de) 2001-07-11
DE59511061D1 (de) 2006-09-21
NO950955D0 (no) 1995-03-13
ATE220070T1 (de) 2002-07-15

Similar Documents

Publication Publication Date Title
FI20051072A (fi) Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö
US6316230B1 (en) Polymerase extension at 3′ terminus of PNA-DNA chimera
US5594117A (en) Polynucleotide reagents containing modified deoxyribose moieties and associated methods of synthesis and use
US8013147B2 (en) Heterocyclic compounds and their use in the detection of nucleic acids
JPH07505903A (ja) オリゴヌクレオチド合成に有用な保護基
EP0251283A2 (en) Poly-labelled oligonucleotide derivative
ATE318273T1 (de) Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
US6063571A (en) Process for amplifying nucleic acids using DNA/PNA primers
CA2382631A1 (en) Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
CA2436665A1 (en) Nucleic acid derivatives
WO1992000989A1 (en) Non-isotopic nucleic acid labelling method
Obayashi et al. Enzymatic synthesis of labeled DNA by PCR using new fluorescent thymidine nucleotide analogue and superthermophilic KOD dash DNA polymerase
US20040214221A1 (en) High density labeling of DNA with modified or "chromophore" carrying nucleotides and DNA polymerases used
ES2252011T3 (es) Marcado de alta densidad de dna con nucleotidos modificados o que llevan un cromoforo y dna-polimerasas empleadas.
DE10328813A1 (de) Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA-Sequenzen mittels triplexbildender Oligomere
DD265429A1 (de) Verfahren zur nichtradioaktiven markierung von polynukleotiden
WO2003072814A2 (en) Improved method for allele-specific pcr
Hinz et al. Synthesis and properties of 2′-deoxycytidine triphosphate carrying c-myc tag sequence